Published in Arch Pharm Res on June 01, 2003
Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med (2012) 4.47
A "perfect storm". Conn Med (2007) 3.32
A role for primary cilia in glutamatergic synaptic integration of adult-born neurons. Nat Neurosci (2012) 1.90
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol (2003) 1.60
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res (2007) 1.56
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res (2008) 1.54
The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol (2003) 1.44
Planar spindle orientation and asymmetric cytokinesis in the mouse small intestine. J Histochem Cytochem (2007) 1.37
HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog (2008) 1.29
Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol (2012) 1.29
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res (2006) 1.26
The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem (2004) 1.23
Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta (2006) 1.19
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther (2008) 1.13
Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene (2004) 1.08
mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie (2010) 1.07
Deoxycholic acid promotes the growth of colonic aberrant crypt foci. Mol Carcinog (2007) 1.06
Evidence for a second wave of oligodendrogenesis in the postnatal cerebral cortex of the mouse. J Neurosci Res (2003) 1.06
Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res (2004) 1.04
Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis (2010) 1.04
Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) (2011) 1.03
Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci (2011) 1.02
Intestinal lineage commitment of embryonic stem cells. Differentiation (2010) 1.01
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Microgenomics: Identification of new expression profiles via small and single-cell sample analyses. Cytometry A (2004) 0.99
Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett (2006) 0.98
Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett (2008) 0.97
Neutralization of inhibitory molecule NG2 improves synaptic transmission, retrograde transport, and locomotor function after spinal cord injury in adult rats. J Neurosci (2013) 0.96
Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res (2005) 0.96
Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. Cancer Lett (2006) 0.95
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis (2003) 0.95
Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy. Cancer Causes Control (2011) 0.93
CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse. J Leukoc Biol (2010) 0.93
Epigenetic alterations in RASSF1A in human aberrant crypt foci. Carcinogenesis (2006) 0.92
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog (2007) 0.91
A model-based analysis of chemical and temporal patterns of cuticular hydrocarbons in male Drosophila melanogaster. PLoS One (2007) 0.90
Suppression of colon carcinogenesis by targeting Notch signaling. Carcinogenesis (2013) 0.90
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem (2005) 0.90
The induction of aberrant crypt foci (ACF) in the colons of rats by trihalomethanes administered in the drinking water. Cancer Lett (2002) 0.89
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila) (2011) 0.89
Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer. Carcinogenesis (2006) 0.89
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol Carcinog (2011) 0.89
Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice. Cancer Prev Res (Phila) (2010) 0.88
Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr Cancer (2004) 0.87
Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res (2002) 0.87
Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res (2005) 0.87
Adaptation of molecular circadian clockwork to environmental changes: a role for alternative splicing and miRNAs. Proc Biol Sci (2013) 0.86
Screening colonoscopy through telephone outreach without antecedent provider visits: a pilot study. Prev Med (2008) 0.86
Suppression of kinesin expression disrupts adenomatous polyposis coli (APC) localization and affects beta-catenin turnover in young adult mouse colon (YAMC) epithelial cells. Exp Cell Res (2002) 0.85
Increased frequency of serrated aberrant crypt foci among smokers. Am J Gastroenterol (2010) 0.85
Nanoproteomic analysis of extracellular receptor kinase-1/2 post-translational activation in microdissected human hyperplastic colon lesions. Proteomics (2013) 0.84
Utilizing endoscopic technology to reveal real-time proteomic alterations in response to chemoprevention. Proteomics Clin Appl (2007) 0.84
Vitamin D resistance and colon cancer prevention. Carcinogenesis (2011) 0.83
Dietary methyl donor depletion protects against intestinal tumorigenesis in Apc(Min/+) mice. Cancer Prev Res (Phila) (2012) 0.82
The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells. Nutr Cancer (2008) 0.82
Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol (2013) 0.82
cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci (2010) 0.81
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog (2003) 0.81
Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability. Cancer Causes Control (2008) 0.80
Azoxymethane-induced pre-adipocyte factor 1 (Pref-1) functions as a differentiation inhibitor in colonic epithelial cells. Carcinogenesis (2004) 0.80
Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells. Mol Carcinog (2012) 0.80
Oxidative damage in colon and mammary tissue of the HFE-knockout mouse. Free Radic Biol Med (2003) 0.80
p53 and its co-activator p300 are inversely regulated in the mouse colon in response to carcinogen. Toxicol Lett (2003) 0.79
Small bowel obstruction as a unique complication of squamous cell carcinoma of the penis. J Clin Gastroenterol (2002) 0.79
Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog (2005) 0.79
Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors. Biochem Pharmacol (2006) 0.78
Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial". Cancer Prev Res (Phila) (2008) 0.78
The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci (2007) 0.78
Chlorogenic acid differentially alters hepatic and small intestinal thiol redox status without protecting against azoxymethane-induced colon carcinogenesis in mice. Nutr Cancer (2010) 0.78
Strain-specific homeostatic responses during early stages of Azoxymethane-induced colon tumorigenesis in mice. Int J Oncol (2007) 0.77
Infliximab-induced psoriaform rash. Clin Gastroenterol Hepatol (2010) 0.76
Colorectal cancer. Mutat Res (2010) 0.75
Multistage gene expression profiling in a differentially susceptible mouse colon cancer model. Cancer Lett (2003) 0.75